Angiopoietin-like 3

Angiopoietin-like 3

Angiopoietin-like 3 분자 정보

Molecule Name
Angiopoietin like 3
분자 별명
ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2
Drug Development Progress
임상 약물 수14
시판 약물 수1
최고 연구 개발 단계Approved
표적 별명
Angiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
분자 배경
Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Angiopoietin-like 3 제품 목록

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
ZodasiranARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals)Phase 3 ClinicalRoche Ltd
Dyslipidemias; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypertriglyceridemia
상세
LNA-043LNA-043Phase 2 ClinicalNovartis Pharma Ag
Knee Injuries; Osteoarthritis; Osteoarthritis, Knee
상세
VupanorsenISIS-703802; PF-07285557Phase 2 ClinicalIonis Pharmaceuticals Inc
Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Homozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
상세
EDP-167EDP-167; EDP167Phase 2 ClinicalEteng Pharmaceutical (Zhuhai) Co Ltd
Dyslipidemias; Homozygous familial hypercholesterolemia
상세
ALN-ANG3ALN-ANG3Phase 2 ClinicalAlnylam Pharmaceuticals Inc
Diabetic Nephropathies
상세
BW-00112BW-00112; BW00112Phase 2 ClinicalShanghai Argo Biopharmaceutical Co Ltd
Dyslipidemias; Hypertriglyceridemia
상세
SolbinsiranLY-3561774; DCR-CM-1; DCR-CM1Phase 2 ClinicalDicerna Pharmaceuticals Inc
Cardiovascular Diseases; Dyslipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases
상세
JS-401JS-401; RP-912Phase 1 ClinicalRisen (Suzhou) Pharma Tech Co Ltd
Hyperlipidemias; Metabolic Diseases
상세
VERVE-201VERVE-201Phase 1 ClinicalBroad Institute, Harvard University
Atherosclerosis; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia
상세
SYH-2070SYH2070; SYH-2070Phase 1 ClinicalCspc Heibei Zhongrun Pharmaceutiacl Co Ltd
Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia
상세
NN-6491NN6491; NN-6491Phase 1 ClinicalNovo Nordisk A/S
Cardiovascular Diseases
상세
NNC0491-6075NNC0491-6075; NNC04916075Phase 1 ClinicalNovo Nordisk A/S
Dyslipidemias
상세
AZD-1705AZD1705; AZD-1705Phase 1 ClinicalAstrazeneca Plc, Parexel International Corp
Cardiovascular Diseases
상세
CTX-310CTX-310; CTX310Phase 1 ClinicalCrispr Therapeutics Ag
Cardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases; Sitosterolemia
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
EvinacumabREGN-1500ApprovedRegeneron Pharmaceuticals IncEvkeezaUnited StatesHypercholesterolemia; Homozygous familial hypercholesterolemiaRegeneron Pharmaceuticals Inc2021-02-11
Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia; Metabolic Diseases
상세